Comorbidities in patients with chronic obstructive lung disease and COVID-19 in Almaty (Kazakhstan Republic)
https://doi.org/10.18093/0869-0189-2022-32-6-923-926
Abstract
SARS-CoV-2 (Severe Acute Respiratory Syndrome-related CoronaVirus 2) infection is characterized by multi-comorbidity, which increases the severity of the disease. The aim of the study was to identify the relationship between the length of stay in the hospital and the comorbidity and the severity of lung damage. Methods. 72 patients with COVID-19 (COronaVIrus Disease 2019) infection were studied, including 33 women and 39 men who were treated in the city hospitals. The average age was 67.4 ± 12.02 years. The SARS-CoV-2 RNA virus was identified by PCR in 46 (63.8%) patients. Results. The most common comorbidities in chronic obstructive pulmonary disease (COPD) patients with COVID-19 included arterial hypertension (in 32%), coronary artery disease (17%), and type 2 diabetes (10%). The majority of patients (48.7%) had the CT II stage. The total proportion of patients with an advanced damage (corresponding to CT III - IV) was 36.2%. Mean hospitalization length was 13.8 ± 7.9 days. Conclusion. COPD patients with COVID-19 infection included a significant percentage of patients with arterial hypertension, which required additional treatment.
Supporting agencies: Grant of the Ministry of Science and Higher Education of the Republic of Kazakhstan (AP09561834) issued to T.A.Muminov. The authors express their gratitude to managers of Asfendiyarov Kazakh National Medical University for supporting the research.
About the Authors
G. U. Esetova
Asfendiyarov Kazakh National Medical University
Kazakhstan
Competing Interests:
Kazakhstan
Gulstan U. Esetova - Candidate of Medicine, Head of the Department of Pulmonology, Asfendiyarov Kazakh National Medical University.
Tole bi 90, Almaty, 050012
tel.: (7771) 448-69-55
Competing Interests:
The authors declare absence of conflict of interests.
L. R. Idrisova
Asfendiyarov Kazakh National Medical University
Kazakhstan
Competing Interests:
Kazakhstan
Leyla R. Idrisova - Candidate of Medicine, Associate Professor, Asfendiyarov Kazakh National Medical University.
Tole bi 90, Almaty, 050012
tel.: (727) 338-70-90
Competing Interests:
The authors declare absence of conflict of interests.
S. S. Salimova
Asfendiyarov Kazakh National Medical University
Kazakhstan
Competing Interests:
Kazakhstan
Suyumbike S. Salimova - Associate Professor, Asfendiyarov Kazakh National Medical University.
Tole bi 90, Almaty, 050012
tel.: (727) 338-70-90
Competing Interests:
The authors declare absence of conflict of interests.
B. Konysbay
Asfendiyarov Kazakh National Medical University
Kazakhstan
Competing Interests:
Kazakhstan
Bakyt Konysbay - Resident, Department of Pulmonology, Asfendiyarov Kazakh National Medical University.
Tole bi 90, Almaty, 050012
tel.: (727) 338-70-90
Competing Interests:
The authors declare absence of conflict of interests.
D. Batyrbay
Asfendiyarov Kazakh National Medical University
Kazakhstan
Competing Interests:
Kazakhstan
Darakyz Batyrbay - Resident, Department of Pulmonology, Asfendiyarov Kazakh National Medical University.
Tole bi 90, Almaty, 050012
tel.: (727) 338-70-90
Competing Interests:
The authors declare absence of conflict of interests.
T. A. Muminov
Asfendiyarov Kazakh National Medical University
Kazakhstan
Competing Interests:
Kazakhstan
Talgat A. Muminov - Doctor of Medicine, Academician of the National Academy of Sciences, Kazakhstan Republic, Professor, Department of Pulmonology, Asfendiyarov Kazakh National Medical University; Member of the International Union against Tuberculosis and Pulmonary Diseases, Academician, Hamburg Academy of Medicine and Prevention, Polish Medical Academy, President, Association of Phthisiologists of the Kazakhstan Republic.
Tole bi 90, Almaty, 050012
tel.: (7777) 211-90-97
Competing Interests:
The authors declare absence of conflict of interests.
References
1. Grinevich V.B., Gubonina I.V., Doshchitsin V.L. et al. [Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020]. Kardiovaskulyarnaya terapiya i profilaktika. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630 (in Russian).
2. Baradaran A., Ebrahimzadeh M.H., Baradaran A., Kachooei A.R. Prevalence of comorbidities in COVID-19 patients: a systematic review and meta-analysis. Arch. Bone Jt Surg. 2020; 8 (Suppl. 1): 247-255. DOI: 10.22038/abjs.2020.47754.2346.
3. Salidat Kairbekova National Research Center for Health Development. [Information and clinical protocol “Coronavirus infection COVID-19”]. Available at: http://www.rcrz.kz/index.php/ru/2017-03-12-10-50-44/press-reliz/1966-informatsiya-o-klinicheskom-pro-tokole-koronavirusnaya-infektsiya-covid-19 (in Russian).
4. Rothlin R.P., Duarte M., Pelorosso F.G. et al. Angiotensin receptor blockers for COVID-19: pathophysiological and pharmacological considerations about ongoing and future prospective clinical trials. Front. Pharmacol. 2021; 12: 603736. DOI: 10.3389/fphar.2021.603736.
Supplementary files
Review
For citations:
Esetova G.U., Idrisova L.R., Salimova S.S., Konysbay B., Batyrbay D., Muminov T.A. Comorbidities in patients with chronic obstructive lung disease and COVID-19 in Almaty (Kazakhstan Republic). PULMONOLOGIYA. 2022;32(6):923-926. (In Russ.) https://doi.org/10.18093/0869-0189-2022-32-6-923-926
Views:
673
Email this article 